Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 17 hydroxyprogesterone caproate Clear all
Terminated No phase listed Observational

17-OHPC in Pregnancy: IM vs SC Routes

NCT04183452
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 6, 2026, 6:51 PM EDT
Withdrawn Phase 2 Interventional

Androgen Reduction in Congenital Adrenal Hyperplasia

NCT03548246
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Abiraterone acetate, Placebo, Hydrocortisone, Fludrocortisone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 9 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Sep 6, 2026, 6:51 PM EDT
Completed No phase listed Observational

Precision Medicine for Preterm Birth

NCT02173210
View directory record Official record
Conditions
Premature Birth
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

NCT01004029
View directory record Official record
Conditions
Preterm Birth
Interventions
Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL, Vehicle
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
41
States / cities
Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing IM vs. Vaginal Progesterone for Pre-term Birth

NCT00579553
View directory record Official record
Conditions
Infant, Premature, Premature Birth
Interventions
Intramuscular Progesterone, Vaginal Progesterone
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 6, 2026, 6:51 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth

NCT03292731
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone caproate 250mg or 500 mg., Safety study of 500 mg dose.
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
5
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies

NCT00135902
View directory record Official record
Conditions
Preterm Birth
Interventions
17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement, 17 alpha-hydroxy progesterone caproate and Placebo supplement
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522
View directory record Official record
Conditions
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 6, 2026, 6:51 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

NCT02913495
View directory record Official record
Conditions
Premature Birth
Interventions
Vaginal Progesterone, Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Springfield, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

NCT00099164
View directory record Official record
Conditions
Preterm Birth, Pregnancy, Multifetal
Interventions
17 alpha-hydroxyprogesterone caproate (17P)
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

17OHP-C Dosing Among Obese Pregnant Women

NCT03433040
View directory record Official record
Conditions
Premature Birth, Absorption; Chemicals
Interventions
17-Hydroxyprogesterone Capronate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Tampa, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 6, 2026, 6:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery

NCT00457886
View directory record Official record
Conditions
Preterm Delivery
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

NCT03257462
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Interventions
SPR001
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Orange, California • San Diego, California • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

NCT01119963
View directory record Official record
Conditions
Preterm Delivery
Interventions
17-alpha-hydroxy-progesterone caproate, Makena®, Castor Oil (Placebo)
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
15
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies

NCT00163020
View directory record Official record
Conditions
Preterm Birth
Interventions
17-alpha-hydroxyprogesterone caproate injectable, Placebo
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 6, 2026, 6:51 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix

NCT00694967
View directory record Official record
Conditions
Mid Trimester Cervical Shortening
Interventions
McDonald cerclage placement, 17 hydroxyprogesterone caproate
Procedure · Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2008 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood

NCT01899846
View directory record Official record
Conditions
Pregnancy
Interventions
Hydroxyprogesterone caproate 250 mg/ml
Drug
Lead sponsor
Lumara Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Lake Worth, Florida • Idaho Falls, Idaho • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 6, 2026, 6:51 PM EDT
Withdrawn No phase listed Observational

fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo

NCT00156000
View directory record Official record
Conditions
Preterm Delivery, Preterm Birth
Interventions
Fetal Fibronectin, Salivary Estriol
Device
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Mesa, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.

NCT01050647
View directory record Official record
Conditions
Pregnancy Complications
Interventions
17-Hydroxyprogesterone Caproate, Caster Oil injections
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 6, 2026, 6:51 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

NCT00439374
View directory record Official record
Conditions
Preterm Delivery, Cervical Length
Interventions
17 alpha-hydroxyprogesterone caproate, Placebo Oil
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Sep 6, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacology of 17-OHPC in Pregnancy

NCT00409825
View directory record Official record
Conditions
Pregnancy
Interventions
17-OHPC, Blood Draws
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 6, 2026, 6:51 PM EDT